Lipitor
"Lower is better" was the positioning. The market-shaping programme behind it, from new cholesterol targets to accepted surrogate endpoints, made it inevitable.
- $150Blifetime revenue
- 4Mcardiovascular events averted
Pharmaceutical Positioning · Mike Rea
35+ years inside pharma's biggest positioning decisions, with a direct hand in more than half of the blockbuster launches of the last 20 years. POSITION is the field guide to pharmaceutical market shaping: eight levers that get the market ready before your product arrives.
The POSITION framework
A field guide to the decisions that move pharmaceutical brands from overlooked to indispensable.
Redefine what counts as success. Shift the baseline so today's standard of care looks inadequate.
Rally KOL networks and advisory boards to co-author publications and symposia, seeding credibility and urgency.
Translate one value proposition into three currencies at once: evidence for the physician, return on investment for the payer, empowerment for the patient.
Get your endpoint, comparator and patient population into the guidelines and advocacy positions that steer prescribing and coverage.
Lay epidemiology and failure-rate data over the category until the unmet need is undeniable, turning a statistic into an imperative a committee can't wave away.
Push for the regulatory pathways (breakthrough designations, accepted surrogate endpoints, orphan status) that de-risk your programme and widen who becomes eligible for it.
Generate the trials, RWE, PROs and health-economic models that every other lever spends as currency.
Once belief is moving, build the feedback loops (patient advocacy, prescriber peer networks, payer case studies) that make adoption self-reinforcing instead of something you keep having to buy.
These are not eight separate workstreams. They are one system.
Strategy in practice
Three cases from POSITION, read against the method: a masterclass, a contest still being decided, and a recovery the market forced.
"Lower is better" was the positioning. The market-shaping programme behind it, from new cholesterol targets to accepted surrogate endpoints, made it inevitable.
Two molecules, one category, and the lead changed hands while the book was being written. Novo chose the position. Lilly chose the molecule.
Extraordinary LDL data, launched as "the most effective LDL lowerer" into a market that needed "for these patients", not "better". The recovery was available at launch.
About Mike Rea
Not positionings. Hopes wearing the costume of a claim.
Mike Rea is the founder of IDEA Pharma and creator of the Pharmaceutical Innovation Index, and has spent 35+ years inside the decisions that turn molecules into medicines.
About MikePrior work
The argument behind the field guide. Deep Positioning showed why the gap between strong science and a weak position exists. POSITION shows how to close it.
Who it's for
Written for the people who make positioning decisions inside pharma and biotech: brand, launch, medical affairs and market access teams.
The market has to be ready before the product arrives. Most of the levers start in Phase II, years before filing, not in the launch plan.
Levers you'll pull
Better on paper, lost in practice. Recovery usually means a narrower segment, the right comparator, and a story each stakeholder can repeat.
Levers you'll pull
If every competitor can say it, it is not a position. Replace "best" with words that are sharper, narrower and harder to steal.
Levers you'll pull
About Mike
Mike Rea has spent more than 35 years inside pharma and biotech's biggest positioning decisions, with direct involvement in more than half of the blockbuster launches of the last 20 years. He founded IDEA Pharma, created the Pharmaceutical Innovation Index, and wrote POSITION.
"Positioning is not what you do to a mind. It is what you do to a product, before there is one."
Most pharmaceutical brands don't fail because the science is weak. They fail because no one can say, in one sentence, why a doctor or patient should choose them over what's already on the shelf.